Brief: Mabpharm Announces Acquisition Of CMAB807
01/03/2021 15:32
March 1 (Reuters) - Mabpharm Ltd 2181.HK :
* TAIZHOU PHARMACEUTICAL TO BUY WORLDWIDE, EXCLUSIVE &
PERPETUAL
LICENSE FOR RIGHTS TO USE ALL PATENTS, PRODUCTS & TECHNOLOGIES
OF CMAB807
* ACQUISITION OF CMAB807 FOR TOTAL CONSIDERATION OF RMB70
MILLION
* UNDER CLINICAL TRIALS AGREEMENT, BIOMABS WILL CONTINUE &
COMPLETE PHASE III TRIALS OF CMAB807 IN PRC
Source text https://www1.hkexnews.hk/listedco/listconews/sehk/2021/0301/2021030103766.pdf
Further company coverage: 2181.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mabpharm
See all newsBrief: Mabpharm Says NMPA Approves CMAB807X (Denosumab Injection) NDA
Brief: Mabpharm Says NMPA Approves Cmab807 (Denosumab Injection) NDA
Brief: Mabpharm FY Profit And Total Comprehensive Income Attributable Rmb57.1 Million
Brief: Mabpharm Says Approval From Drug Regulatory Authority Of Pakistan On Registration Of Core Product,CMAB008
Brief: Mabpharm Says Approval From Indonesian National Agency Of Drug And Food Control Of CMAB008